Czechia vs Lithuania: HIV/AIDS deaths averted by antiretroviral therapy
Czechia
150 deaths
in 2022
Lithuania
141.25 deaths
in 2024
Czechia rank
117th
Lithuania rank
119th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Czechia
- Lithuania
How they compare
Czechia currently reports 150 deaths against 141.25 deaths in Lithuania, a difference of 8.75 deaths.
That makes Czechia's figure about 1.1 times Lithuania's.
The two have swapped places 1 time across 33 shared years of data; in 1990 it was Lithuania ahead.
Czechia ranks 117th and Lithuania ranks 119th of 157 countries.
Czechia has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Czechia | Lithuania | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 3.9 deaths | 0 deaths | 3.9 deaths | Czechia |
| 2000s | 41.6 deaths | 14.47 deaths | 27.13 deaths | Czechia |
| 2010s | 104.7 deaths | 79.24 deaths | 25.46 deaths | Czechia |
| 2020s | 148 deaths | 122.56 deaths | 25.44 deaths | Czechia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Czechia or Lithuania?
- Czechia, at 150 deaths against 141.25 deaths in Lithuania as of 2022.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Czechia and Lithuania?
- 8.75 deaths, with Czechia ahead.
- How many years of comparable data are there for Czechia and Lithuania?
- 33 years are reported by both, from 1990 to 2022.
- How do Czechia and Lithuania rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Czechia ranks 117th and Lithuania ranks 119th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.